About Jonathan Zung, PhD

As a member of the Covance Global Operating Committee, Dr. Zung is responsible for overseeing Early Clinical Services, Phase II-IV Clinical Development and Market Access Services. He is a proven R&D leader with more than two decades of biopharmaceutical experience in all phases of drug development. Prior to joining Covance, Dr. Zung was vice president and head of Global Clinical Sciences and Operations at UCB, vice president and head of Global Development Operations at Bristol-Myers and had various leadership positions at Pfizer Global Research and Development. He received his doctorate in analytical chemistry from Emory University in Atlanta, Georgia and a bachelor’s degree in chemistry from the Florida Institute of Technology in Melbourne, Florida.

Patient Centricity and the Role of the CRO

Biopharmaceutical companies both big and small have witnessed the shift toward patient-centric practices in the current healthcare landscape. As a result, many are now including or planning to incorporate the voice of the patient in their drug Patient Centricity and the Role of the CROdevelopment strategy.

How do clinical research organizations (CROs) respond and support this increasing focus on patient-centric practices? We recently spoke to Jonathan Zung, PhD, group president, clinical development and commercialization services at Covance to understand his view on the patient centricity imperative and how it impacts clinical development activities.
Continue reading